Table 4.
a |
Uropygial gland volume |
|
|
|
|
|
|
|
Females |
|
|
Estimate ± SE |
df |
F |
P |
|
|
Date |
|
0.01 ± 0.01 |
1,50 |
4.25 |
0.04 |
|
|
Year |
|
0.15 ± 0.04 |
1,50 |
13.89 |
<0.001 |
|
|
Wing length |
|
0.41 ± 0.13 |
1,50 |
10.6 |
0.002 |
|
Males |
|
Estimate ± SE |
df |
F |
P |
|
|
|
Date |
|
−0.01 ± 0.004 |
1,36 |
7,0 |
0.01 |
|
|
Year |
|
0.21 ± 0.06 |
1,36 |
13,0 |
0.001 |
|
|
Body condition |
|
0.16 ± 0.04 |
1,36 |
12.5 |
0.001 |
|
|
Treatment |
Nisin |
0.16 ± 0.07 |
2,36 |
4.3 |
0.02 |
|
|
|
TSB |
0.16 ± 0.06 |
|
|
|
b |
Uropygial gland composition - PC2 |
|
|
|
|
|
|
|
Females |
|
|
Estimate ± SE |
df |
F |
P |
|
|
Date |
|
0.07 ± 0.03 |
1,27 |
5.5 |
0.03 |
|
|
Treatment |
Nisin |
2.38 ± 0.69 |
2,27 |
6.5 |
0.005 |
|
|
|
TSB |
1.95 ± 0.71 |
|
|
|
|
Males |
|
Estimate ± SE |
df |
F |
P |
|
Body condition | −0.51 ± 0.22 | 1,21 | 5.4 | 0.03 |
The compounds produced and their contribution to the principal components are given in Table 1. The table present final models after backward selection. Treatment effects estimates compared to the control are shown.